Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00181688 · ClinicalTrials.gov registry record · Phase 2

Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer

A Phase 2 study of Ovarian Cancer and Peritoneal Carcinoma, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 2
Development phase
35
Enrollment target
2
Study locations

NCT00181688: Completed Phase 2 study of Ovarian Cancer and Peritoneal Carcinoma, sponsored by Massachusetts General Hospital.

NCT00181688 is a Phase 2 study of Ovarian Cancer and Peritoneal Carcinoma that has completed, run by Massachusetts General Hospital. The registered enrollment target is 35 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00181688, a Phase 2 study of Ovarian Cancer and Peritoneal Carcinoma, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 2
Development phase
35 participants
Enrollment target
2
Study locations

Study Summary

The main purpose of this study is to determine the effects (good and bad) Iressa plus anastrozole has on patients with relapsed ovarian cancer.

Conditions Studied

Ovarian Cancer Peritoneal Carcinoma Tubal Carcinoma

Interventions

  • DRUG Iressa (ZD1839)
  • DRUG Arimidex (Anastrozole)

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2003-10
Est. Completion 2006-03
Phase Phase 2
Massachusetts General Hospital

2,032 total trials

What the finished NCT00181688 record still lists

NCT00181688 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower).

The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Iressa (ZD1839) is the first listed.

NCT00181688 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00181688 about?

NCT00181688 is a clinical study titled "Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer". The main purpose of this study is to determine the effects (good and bad) Iressa plus anastrozole has on patients with relapsed ovarian cancer.

What is the current status of trial NCT00181688?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2003-10. Estimated completion is 2006-03.

What conditions does trial NCT00181688 study?

This clinical trial studies the following conditions: Ovarian Cancer, Peritoneal Carcinoma, Tubal Carcinoma.

What interventions are being tested in trial NCT00181688?

The interventions under investigation include: Iressa (ZD1839) (DRUG), Arimidex (Anastrozole) (DRUG).

Who is sponsoring clinical trial NCT00181688?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00181688 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00181688's enrollment target sits among peer trials

35 237th of 322 higher than 81 of 322 other Ovarian Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01697371 · 35 participants · NA

    Proton Therapy in the Treatment of Liver Metastases

  • NCT01940757 · 35 participants · Phase 1

    Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

  • NCT02235857 · 35 participants · NA

    Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

  • NCT02637934 · 35 participants · Phase 1

    Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00181688, the US trial registry maintained by the National Library of Medicine. NCT00181688 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.